{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:11:01Z","timestamp":1789193461755,"version":"build-2803163510"},"reference-count":38,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"unspecified","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U54-DK106829"],"award-info":[{"award-number":["U54-DK106829"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fred Hutchinson Cancer Center Immunotherapy Integrated Research Center","award":["20016117"],"award-info":[{"award-number":["20016117"]}]},{"DOI":"10.13039\/100016947","name":"Swim Across America","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100016947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2033771"],"award-info":[{"award-number":["2033771"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Society for Cell and Gene Therapy","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100001906","name":"Washington Research Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001906","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010235","name":"Anthony Rothe Memorial Trust","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100010235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5K12CA076930-25"],"award-info":[{"award-number":["5K12CA076930-25"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Washington Department of Medicine","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"CLEARbridge Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,10,28]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The translational study of chimeric antigen receptor (CAR) T-cell function, persistence, immunophenotype, and spatial localization after infusion is crucial for understanding factors that influence clinical outcomes. However, research has been limited by a lack of optimized tools to reliably detect CAR-engineered cells. To address this, we developed a novel platform to generate monoclonal antibodies (mAbs) targeting a linker peptide incorporated in single-chain variable fragments (scFvs) of most CAR constructs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using recombinant proteins and scFv linker peptides as immunogens, we generated murine mAbs against the Whitlow linker peptide, capable of binding cells expressing Whitlow linker-containing CARs in both fresh and formalin-fixed paraffin-embedded (FFPE) tissues. We evaluated these antibodies in multiple in vitro translational applications relevant to CAR T-cell research and manufacturing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified five unique mAbs reactive against the Whitlow linker and characterized their binding properties and three-dimensional structural conformation. One clone was evaluated in depth, demonstrating comparable capacity to identify CAR T cells in peripheral blood relative to other methods using anti-idiotype antibodies or recombinant CAR-target proteins. In contrast to these reagents, the anti-Whitlow mAb detects cells expressing Whitlow linker-containing CARs with different antigen specificities, including those harboring the widely employed anti-CD19 FMC63-derived scFv as well as other scFvs, such as those targeting B-cell maturation antigen (BCMA) or CD33. Importantly, the anti-Whitlow mAb identified CAR T cells in situ in archival FFPE tissues, and a DNA-barcoded format enabled their spatial characterization and immunophenotyping in highly multiplexed immunohistochemistry. We also assessed the functional consequences of antibody binding on CAR T cells in vitro and demonstrated the feasibility of anti-Whitlow mAb-mediated selective enrichment of CAR-expressing T cells for potential utility in manufacturing workflows.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Anti-Whitlow mAb clones exhibited distinct structural and functional properties that can be leveraged for multiple applications, providing versatile tools for detection, selection and manipulation of a broad range of clinical and preclinical CAR T-cell products.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013123","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T13:15:13Z","timestamp":1763471713000},"page":"e013123","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARs"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct01865617","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1885-1773","authenticated-orcid":false,"given":"Erik L","family":"Kimble","sequence":"first","affiliation":[{"name":"Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"},{"name":"Hematology and Oncology Division, University of Washington Department of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-0847","authenticated-orcid":false,"given":"Jocelyn H","family":"Wright","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Torkelson","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delaney R","family":"Kirchmeier","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5362-1556","authenticated-orcid":false,"given":"Kristina","family":"Braathen","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond O","family":"Ruff","sequence":"additional","affiliation":[{"name":"Ben Towne Center for Childhood Cancer Research and Blood Disorders, Seattle Children\u2019s Research Institute, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen R","family":"Shimp","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon W","family":"Seaton","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-8409","authenticated-orcid":false,"given":"Jordan","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orpheus","family":"Kolokythas","sequence":"additional","affiliation":[{"name":"University of Washington Department of Radiology, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman E","family":"Boiani","sequence":"additional","affiliation":[{"name":"Antibody Technology Core, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jellyman","sequence":"additional","affiliation":[{"name":"Antibody Technology Core, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia CS","family":"Yeung","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tam","sequence":"additional","affiliation":[{"name":"Antibody Technology Core, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason P","family":"Price","sequence":"additional","affiliation":[{"name":"Ben Towne Center for Childhood Cancer Research and Blood Disorders, Seattle Children\u2019s Research Institute, Seattle, Washington, USA"},{"name":"University of Washington Department of Pediatrics, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7980-3882","authenticated-orcid":false,"given":"Alexandre","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J","family":"Turtle","sequence":"additional","affiliation":[{"name":"Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"},{"name":"The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"2026091123002446000_13.11.e013123.1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"2026091123002446000_13.11.e013123.2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026091123002446000_13.11.e013123.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2026091123002446000_13.11.e013123.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009098"},{"key":"2026091123002446000_13.11.e013123.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"2026091123002446000_13.11.e013123.6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17474086.2024.2420614","article-title":"Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia","volume":"17","author":"Colonne","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"2026091123002446000_13.11.e013123.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.omton.2024.200854","article-title":"Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy","volume":"32","author":"Fiorenza","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"2026091123002446000_13.11.e013123.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01800-8"},{"key":"2026091123002446000_13.11.e013123.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"2026091123002446000_13.11.e013123.10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"key":"2026091123002446000_13.11.e013123.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-883710"},{"key":"2026091123002446000_13.11.e013123.12","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-116745","article-title":"Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed\/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","volume":"132","author":"Hirayama","year":"2018","journal-title":"Blood"},{"key":"2026091123002446000_13.11.e013123.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-887067"},{"key":"2026091123002446000_13.11.e013123.14","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.142","article-title":"PD-L1+ macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacy","volume":"8","author":"Hirayama","year":"2024","journal-title":"Hemasphere"},{"key":"2026091123002446000_13.11.e013123.15","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.97"},{"key":"2026091123002446000_13.11.e013123.16","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/6.8.989"},{"key":"2026091123002446000_13.11.e013123.17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32103"},{"key":"2026091123002446000_13.11.e013123.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-021-00556-8"},{"key":"2026091123002446000_13.11.e013123.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-01094-0"},{"key":"2026091123002446000_13.11.e013123.20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008697"},{"key":"2026091123002446000_13.11.e013123.21","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn5631","article-title":"Multiplexed high-throughput immune cell imaging reveals molecular health-associated phenotypes","volume":"8","author":"Severin","year":"2022","journal-title":"Sci Adv"},{"key":"2026091123002446000_13.11.e013123.22","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2565"},{"key":"2026091123002446000_13.11.e013123.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"2026091123002446000_13.11.e013123.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1061-7"},{"key":"2026091123002446000_13.11.e013123.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101158","article-title":"Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFN\u03b3-expressing CD8 T cells","volume":"4","author":"Strati","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026091123002446000_13.11.e013123.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01959-0"},{"key":"2026091123002446000_13.11.e013123.27","doi-asserted-by":"publisher","DOI":"10.1126\/science.2333521"},{"key":"2026091123002446000_13.11.e013123.28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1408766112"},{"key":"2026091123002446000_13.11.e013123.29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3324\/haematol.2022.281110","article-title":"Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T cell therapy","volume":"108","author":"Berger","year":"2023","journal-title":"Haematologica"},{"key":"2026091123002446000_13.11.e013123.30","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21941"},{"key":"2026091123002446000_13.11.e013123.31","doi-asserted-by":"crossref","unstructured":"Grahnert A , Seiffert S , Wenk K , et al . Evaluation of Anti-CAR Linker mAbs for CAR T Monitoring after BiTEs\/bsAbs and CAR T-Cell Pretreatment. Biomedicines 2024;12.","DOI":"10.20944\/preprints202407.0787.v1"},{"key":"2026091123002446000_13.11.e013123.32","doi-asserted-by":"crossref","unstructured":"Turicek DP , Giordani VM , Moraly J , et al . CAR T-cell detection scoping review: an essential biomarker in critical need of standardization. J Immunother Cancer 2023;11.","DOI":"10.1136\/jitc-2022-006596"},{"key":"2026091123002446000_13.11.e013123.33","doi-asserted-by":"crossref","first-page":"101328","DOI":"10.1016\/j.omtm.2024.101328","article-title":"Linker-specific monoclonal antibodies present a simple and reliable detection method for scFv-based CAR NK cells","volume":"32","author":"Schindler","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026091123002446000_13.11.e013123.34","doi-asserted-by":"crossref","unstructured":"Shishido SN , Hart O , Jeong S , et al . Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy. J Immunother Cancer 2024;12.","DOI":"10.1136\/jitc-2023-007329"},{"key":"2026091123002446000_13.11.e013123.35","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","article-title":"CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy","volume":"8","author":"Ledergor","year":"2024","journal-title":"Blood Adv"},{"key":"2026091123002446000_13.11.e013123.36","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134612","article-title":"Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"key":"2026091123002446000_13.11.e013123.37","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4380"},{"key":"2026091123002446000_13.11.e013123.38","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3973"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:00:35Z","timestamp":1789192835000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,18]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/jitc-2025-013123"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013123","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}